Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
Resmed (NYSE:RMD) has launched the Sleep Institute, a global clinical insights initiative aimed at advancing sleep health science and understanding. The initiative debuts at the World Sleep Congress 2025 in Singapore, focusing on addressing the significant global burden of sleep disorders, including 1 billion people affected by obstructive sleep apnea (OSA) and 852 million adults with clinical insomnia.
The Sleep Institute will publish research, expert perspectives, and real-world data to improve diagnosis and inform clinical strategies. A recent U.S. consumer survey revealed that while over 80% of respondents consider sleep important for health, only one-third reported discussing sleep with healthcare providers in the past six months. The initiative will feature a symposium at the World Sleep Congress addressing OSA underdiagnosis, bringing together experts from Iceland, Singapore, the United States, and Sweden.
Resmed (NYSE:RMD) ha lanciato il Sleep Institute, un'iniziativa globale per approfondire la ricerca clinica e la comprensione della salute del sonno. Il progetto viene presentato al World Sleep Congress 2025 a Singapore e mira ad affrontare l'enorme impatto mondiale dei disturbi del sonno, compresi i 1 miliardo di persone colpite dall'apnea ostruttiva del sonno (OSA) e i 852 milioni di adulti con insonnia clinica.
Il Sleep Institute pubblicherà ricerche, prospettive di esperti e dati real-world per migliorare la diagnosi e guidare le strategie cliniche. Un recente sondaggio tra consumatori statunitensi ha rilevato che, pur considerando il sonno importante per la salute per oltre l'80% dei rispondenti, solo circa un terzo ha parlato del sonno con un professionista sanitario negli ultimi sei mesi. L'iniziativa includerà un simposio al World Sleep Congress dedicato alla sotto-diagnosi dell'OSA, con esperti provenienti da Islanda, Singapore, Stati Uniti e Svezia.
Resmed (NYSE:RMD) ha puesto en marcha el Sleep Institute, una iniciativa clínica global destinada a impulsar la ciencia y el conocimiento sobre la salud del sueño. La iniciativa se presenta en el World Sleep Congress 2025 en Singapur y se centra en afrontar la elevada carga mundial de los trastornos del sueño, entre ellos los 1.000 millones de personas afectadas por la apnea obstructiva del sueño (AOS) y los 852 millones de adultos con insomnio clínico.
El Sleep Institute publicará investigaciones, perspectivas de expertos y datos del mundo real para mejorar el diagnóstico e informar las estrategias clínicas. Una encuesta reciente en EE. UU. mostró que, aunque más del 80% de los encuestados considera el sueño importante para la salud, solo alrededor de un tercio habló sobre el sueño con un profesional sanitario en los últimos seis meses. La iniciativa incluirá un simposio en el World Sleep Congress sobre la subdiagnosis de la AOS, reuniendo expertos de Islandia, Singapur, Estados Unidos y Suecia.
Resmed (NYSE:RMD)는 수면 건강 과학과 이해를 발전시키기 위한 글로벌 임상 인사이트 이니셔티브인 Sleep Institute를 출범했습니다. 이 이니셔티브는 싱가포르에서 열리는 World Sleep Congress 2025에서 공개되며, 폐쇄성 수면무호흡증(OSA)에 영향을 받는 10억 명과 임상적 불면증을 겪는 8억 5,2백만 명을 포함한 수면장애의 중대한 전 세계적 부담을 해결하는 데 초점을 맞춥니다.
Sleep Institute는 진단 개선과 임상 전략 수립에 기여하기 위해 연구, 전문가 의견 및 실제 데이터(real-world data)를 발표할 예정입니다. 최근 미국 소비자 조사에서는 응답자의 80% 이상이 수면을 건강에 중요하다고 꼽았지만, 지난 6개월 동안 의료진과 수면에 관해 대화한 사람은 3분의 1에 불과한 것으로 나타났습니다. 이 이니셔티브는 OSA의 진단 미비 문제를 다루는 심포지엄을 World Sleep Congress에서 개최하며, 아이슬란드, 싱가포르, 미국, 스웨덴의 전문가들을 한자리에 모을 예정입니다.
Resmed (NYSE:RMD) a lancé le Sleep Institute, une initiative clinique mondiale visant à faire progresser la science et la compréhension de la santé du sommeil. L'initiative est présentée au World Sleep Congress 2025 à Singapour et s'attaque au lourd fardeau mondial des troubles du sommeil, notamment 1 milliard de personnes souffrant d'apnée obstructive du sommeil (AOS) et 852 millions d'adultes avec une insomnie clinique.
Le Sleep Institute publiera des recherches, des points de vue d'experts et des données du monde réel pour améliorer le diagnostic et orienter les stratégies cliniques. Une récente enquête auprès de consommateurs américains a révélé que si plus de 80 % des répondants jugent le sommeil important pour la santé, seulement environ un tiers en a discuté avec des professionnels de santé au cours des six derniers mois. L'initiative comprendra un symposium au World Sleep Congress sur la sous-détection de l'AOS, réunissant des experts d'Islande, de Singapour, des États-Unis et de Suède.
Resmed (NYSE:RMD) hat das Sleep Institute gestartet, eine globale Initiative für klinische Erkenntnisse zur Förderung der Schlafforschung und des Verständnisses von Schlafgesundheit. Die Initiative wird beim World Sleep Congress 2025 in Singapur vorgestellt und richtet sich darauf, die erhebliche weltweite Belastung durch Schlafstörungen anzugehen, darunter 1 Milliarde Menschen mit obstruktiver Schlafapnoe (OSA) und 852 Millionen Erwachsene mit klinischer Insomnie.
Das Sleep Institute wird Forschung, Expertenmeinungen und Real-World-Daten veröffentlichen, um Diagnosen zu verbessern und klinische Strategien zu unterstützen. Eine aktuelle US-Verbraucherumfrage zeigte, dass zwar über 80 % der Befragten den Schlaf für wichtig für die Gesundheit halten, aber nur etwa in den vergangenen sechs Monaten mit medizinischem Personal über Schlaf gesprochen hat. Die Initiative umfasst ein Symposium beim World Sleep Congress zur Untererkennung von OSA, bei dem Experten aus Island, Singapur, den USA und Schweden zusammenkommen.
- Launch of a new global clinical insights initiative to advance sleep health science
- Partnership with leading global sleep experts and researchers
- Strategic timing with debut at World Sleep Congress 2025
- Focus on addressing a large market opportunity with 1 billion OSA and 852 million insomnia patients globally
- Initiative is non-commercial, suggesting no direct immediate revenue impact
- Significant gap in sleep disorder diagnosis and treatment remains a challenge
New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health.
Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions, and elevate sleep as a global health priority. The announcement comes ahead of the World Sleep Congress, taking place September 5–10 in Singapore.
Sleep disorders are among the most common health challenges worldwide, with an estimated 1 billion people living with obstructive sleep apnea (OSA)1 and about 852 million adults experiencing clinically relevant insomnia2. Yet, the majority of people remain undiagnosed, fueling higher rates of chronic disease, lost productivity, and rising healthcare costs3. To help address this gap, Sleep Institute publishes original research, expert perspectives, and real-world data to support earlier and more accurate diagnosis and guide more informed clinical, policy, and system-level strategies.
“Sleep Institute reflects Resmed’s commitment to advancing sleep health worldwide,” said Kimberly L. Sterling, vice president, health research at Resmed, on behalf of Sleep Institute. “It’s about moving from awareness to action — giving global health and policy leaders the insights they need to close today’s care gaps and shape tomorrow’s sleep medicine.”
New findings from a U.S. consumer survey conducted by Sleep Institute4 highlight this need. While more than four in five respondents said sleep is important to their overall health, only one in three reported that a doctor or nurse has asked them about their sleep in the past six months. This disconnect illustrates the need to better integrate sleep into routine healthcare and policy discussions, a central focus of Sleep Institute’s work.
Global Collaboration at World Sleep Congress
Sleep Institute will debut at the World Sleep Congress, with an expert led symposium tackling one of sleep medicine’s most pressing challenges: the global underdiagnosis of OSA. The session will examine barriers in diagnostic pathways for OSA and highlight scalable solutions to help improve access and outcomes.
The symposium, OSA Underdiagnosis – A world of difference, a common challenge, brings together clinical leaders from Iceland, Singapore, the United States, and Sweden, including:
- Erna Sif Arnardóttir – director, Reykjavik University Sleep Institute; president, European Sleep Research Society (Iceland)
- Chi-Hang Ronald Lee – professor of medicine, National University of Singapore; senior consultant, National University Heart Centre and Alexandra Hospital (Singapore)
- Michelle R. Zeidler – professor of medicine, University of California, Los Angeles (UCLA); director, VA Greater Los Angeles Sleep Center (U.S.)
- Ludger Grote – medical director, Sleep Disorders Center, Sahlgrenska University Hospital (Sweden)
“There is a clear and urgent need to close the diagnosis gap in sleep disorders such as OSA,” said Michelle R. Zeidler, MD, symposium panelist. “Sleep Institute’s focus on translating evidence into action will help clinicians, policymakers, and health systems take meaningful steps toward earlier detection and more personalized care.”
Through ongoing publications, data releases, and global collaborations, Sleep Institute aims to act as a catalyst for earlier diagnosis, stronger policies, and improved outcomes in sleep health worldwide. Learn more at ResmedSleepInstitute.com.
About Sleep Institute
Sleep Institute is a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Established by Resmed, Sleep Institute collaborates with researchers, clinicians, policymakers, and health system leaders to deliver objective, data-driven insights. Its goal is to help inform care model innovation, support policy development, and reinforce the vital role of sleep in improving health outcomes worldwide. Explore the latest insights at ResmedSleepInstitute.com and follow Sleep Institute on LinkedIn.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For Media | For Investors |
| Julia Moser | Salli Schwartz |
| julia.moser@resmed.de | Salli.Schwartz@resmed.com |
| news@resmed.com | investorrelations@resmed.com |
_________________________________
1 Benjafield AV, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763
2 Benjafield AV, et al. Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis. Sleep Medicine Reviews.2025, https://doi.org/10.1016/j.smrv.2025.102121.
3 American Academy of Sleep Medicine. Hidden Health Crisis: The Economic Burden of Undiagnosed Sleep Apnea. 2016. Available at:https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf
4 Methodology: A third-party provider surveyed 1,000 individuals in the U.S. All respondents were 18 or older, and the sample was census-balanced by age and gender. The third-party survey provider collected data through an online survey fielded from August 18 to 22, 2025. The survey respondents were independently sourced from Veridata Insights.
FAQ
What is the Resmed Sleep Institute and when was it launched?
How many people are affected by sleep disorders globally according to Resmed?
What did Resmed's recent U.S. consumer survey reveal about sleep health awareness?
Who are the key experts participating in Resmed's Sleep Institute symposium at World Sleep Congress 2025?
What is the main goal of Resmed's Sleep Institute initiative?
